Literature DB >> 8496907

Aromatase inhibitors: synthesis, biological activity, and binding mode of azole-type compounds.

P Furet1, C Batzl, A Bhatnagar, E Francotte, G Rihs, M Lang.   

Abstract

The enantiomers of the potent nonsteroidal inhibitor of aromatase fadrozole hydrochloride 3 have been separated and their absolute configuration determined by X-ray crystallography. On the basis of a molecular modeling comparison of the active enantiomer 4 and one of the most potent steroidal inhibitors reported to date, (19R)-10-thiiranylestr-4-ene-3,17-dione, 7, a model describing the relative binding modes of the azole-type and steroidal inhibitors of aromatase at the active site of the enzyme is proposed. It is suggested that the cyanophenyl moiety present in the most active azole inhibitors partially mimics the steroid backbone of the natural substrate for aromatase, androst-4-ene-3,17-dione, 1. The synthesis and biological testing of novel analogues of 3 used to define the accessible and nonaccessible volumes to ligands in the model of the active site of aromatase are reported.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8496907     DOI: 10.1021/jm00062a012

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  11 in total

Review 1.  Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore.

Authors:  Fraser F Fleming; Lihua Yao; P C Ravikumar; Lee Funk; Brian C Shook
Journal:  J Med Chem       Date:  2010-08-30       Impact factor: 7.446

2.  Comparative molecular field analysis of non-steroidal aromatase inhibitors related to fadrozole.

Authors:  M Recanatini
Journal:  J Comput Aided Mol Des       Date:  1996-02       Impact factor: 3.686

3.  Hybrid dual aromatase-steroid sulfatase inhibitors with exquisite picomolar inhibitory activity.

Authors:  L W Lawrence Woo; Christian Bubert; Atul Purohit; Barry V L Potter
Journal:  ACS Med Chem Lett       Date:  2010-12-29       Impact factor: 4.345

4.  Structure of human cortisol-producing cytochrome P450 11B1 bound to the breast cancer drug fadrozole provides insights for drug design.

Authors:  Simone Brixius-Anderko; Emily E Scott
Journal:  J Biol Chem       Date:  2018-11-13       Impact factor: 5.157

Review 5.  Aromatase inhibitors and inactivators for breast cancer therapy.

Authors:  Per E Lønning
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

6.  Insight into the binding interactions of CYP450 aromatase inhibitors with their target enzyme: a combined molecular docking and molecular dynamics study.

Authors:  Roberta Galeazzi; Luca Massaccesi
Journal:  J Mol Model       Date:  2011-06-18       Impact factor: 1.810

Review 7.  Aromatase inhibitors--mechanisms for non-steroidal inhibitors.

Authors:  H V Vanden Bossche; H Moereels; L M Koymans
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

8.  FACE: the barefaced facts of AI potency.

Authors:  Alain Monnier
Journal:  Cancer Manag Res       Date:  2010-10-27       Impact factor: 3.989

9.  Aromatase and dual aromatase-steroid sulfatase inhibitors from the letrozole and vorozole templates.

Authors:  Paul M Wood; L W Lawrence Woo; Mark P Thomas; Mary F Mahon; Atul Purohit; Barry V L Potter
Journal:  ChemMedChem       Date:  2011-05-23       Impact factor: 3.466

10.  Construction of 3D models of the CYP11B family as a tool to predict ligand binding characteristics.

Authors:  Luc Roumen; Marijn P A Sanders; Koen Pieterse; Peter A J Hilbers; Ralf Plate; Erica Custers; Marcel de Gooyer; Jos F M Smits; Ilona Beugels; Judith Emmen; Harry C J Ottenheijm; Dirk Leysen; J J R Hermans
Journal:  J Comput Aided Mol Des       Date:  2007-07-24       Impact factor: 3.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.